scispace - formally typeset
V

Verónica Crisóstomo

Researcher at Carlos III Health Institute

Publications -  73
Citations -  1153

Verónica Crisóstomo is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Myocardial infarction & Medicine. The author has an hindex of 20, co-authored 63 publications receiving 962 citations.

Papers
More filters
Journal ArticleDOI

Benign prostatic hyperplasia: transcatheter arterial embolization as potential treatment--preliminary study in pigs.

TL;DR: Findings suggest that TAE has potential as an alternative treatment for symptomatic benign prostatic hyperplasia in humans, and can induce shrinkage of the prostate without compromising the sexual desire and erectile function of animals.
Journal ArticleDOI

Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 2, Insights into the Technical Rationale.

TL;DR: New insights into the likely mechanisms behind PAE are described, such as ischemia-induced apoptosis, apoptosis enhanced by blockage of androgens circulation to the embolized prostate, secondary denervation following PAE, and potential effect of nitric oxide pathway immediately after embolization.
Journal ArticleDOI

Bispectral index, spectral edge frequency 95%, and median frequency recorded for various concentrations of isoflurane and sevoflurane in pigs

TL;DR: BIS was useful for predicting changes in anesthetic depth at clinical dosages of inhalant anesthetics and for both agents, there was good correlation between VAS scores and BIS values and between Vas scores and SEF values.
Journal ArticleDOI

Endotracheal stenting therapy in dogs with tracheal collapse

TL;DR: The currently available stents and their potential clinical application to the veterinary patient will be discussed and a comparative overview of intra-luminal stenting of the trachea in human and veterinary medicine is provided.
Journal ArticleDOI

Delayed administration of allogeneic cardiac stem cell therapy for acute myocardial infarction could ameliorate adverse remodeling: experimental study in swine

TL;DR: The intracoronary injection of 25x106 allogeneic cardiac stem cells is generally safe, both early and 7 days after experimental infarction, and alleviates myocardial dysfunction, with a greater limitation of left ventricular remodeling when performed at one week.